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brane of mitochondria, and its malonyl-CoA product is
a potent inhibitor of the transport of long-chain acyl-
CoAs for oxidation in the mitochondria (McGarry and
Brown, 1997; Ramsay et al., 2001). Mice lacking ACC2
have elevated fatty acid oxidation, reduced body fat and
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body weight (Abu-Elheiga et al., 2001), indicating the
importance of this enzyme for drug discovery (Abu-
Elheiga et al., 2003; Lenhard and Gottschalk, 2002).Summary
CP-640186 has recently been shown by researchers
at Pfizer Inc. to be a potent inhibitor of both isoformsAcetyl-coenzyme A carboxylases (ACCs) are impor-
tant targets for the development of therapeutic agents of mammalian ACCs (Figure 1B), with IC50 values of
about 55 nM (Harwood et al., 2003). This is currently theagainst obesity, diabetes, and other diseases. CP-
640186 is a potent inhibitor of mammalian ACCs and only reported potent inhibitor of mammalian ACCs. In
cell cultures as well as in animal models, the compoundcan reduce body weight and improve insulin sensitivity
in test animals. It is believed to target the carboxyltran- can reduce tissue malonyl-CoA levels, inhibit fatty acid
biosynthesis, and stimulate fatty acid oxidation. Mostsferase (CT) domain of these enzymes. Here we report
the crystal structure of the yeast CT domain in complex importantly, the compound can reduce body fat mass
and body weight, and improve insulin sensitivity, validat-with CP-640186. The inhibitor is bound in the active
site at the interface of a dimer of the CT domain. CP- ing ACCs as targets for antiobesity and antidiabetes
drugs (Harwood et al., 2003). These observations also640186 has tight interactions with the putative biotin
binding site in the CT domain and demonstrates a suggest that dual inhibitors of both isoforms of mamma-
lian ACCs may be better therapeutic agents than thosedistinct mode of inhibiting the CT activity as compared
to the herbicides that inhibit plant ACCs. The affinity that solely inhibit ACC2 (Harwood et al., 2003). Kinetic
studies show that the compound is noncompetitive ver-of inhibitors for the CT domain has been assessed
using kinetic and fluorescence anisotropy binding sus the acetyl-CoA substrate, but may function at the
active site of the CT domain (Harwood et al., 2003).studies. The structural information identifies three re-
gions for drug binding in the active site of CT. While CP-640186 targets the mammalian ACCs, po-
tent inhibitors of ACCs from some plants have been
widely used as commercial herbicides for more than 30Introduction
years (Devine and Shukla, 2000; Gronwald, 1991). These
herbicides belong to two different chemical classes, asObesity is a serious health problem in both the devel-
oped and developing countries (Hill et al., 2003). In the represented by haloxyfop (FOPs) and sethoxydim (DIMs).
They kill sensitive plants by shutting down fatty acidUS, 30% of the population are obese, while another 35%
are overweight. Moreover, being obese significantly in- biosynthesis. Mutations of either of two residues
(Ile→Leu at one site or Ile→Asn at the other) in the CTcreases the risk for other diseases, especially type 2
diabetes and cardiovascular diseases. There is an ur- domain of plant ACCs can confer resistance to these
herbicides (Delye et al., 2003; Jelenska et al., 2002; Zag-gent need for behavioral changes (food intake and phys-
ical activities) in the general population, as well as thera- nitko et al., 2001), suggesting that the compounds may
interact with the CT domain of ACC. This is also sup-peutic agents to control the spread of this epidemic.
Acetyl-coenzyme A carboxylases (ACCs) are crucial ported by kinetic data on the inhibition of plant ACCs by
these herbicides (Devine and Shukla, 2000; Gronwald,for the metabolism of fatty acids and are promising tar-
gets for drug development against obesity, diabetes, 1991; Rendina et al., 1990).
and other diseases. ACCs catalyze the conversion of We recently reported the crystal structures of the free
acetyl-CoA to malonyl-CoA (Abu-Elheiga et al., 2001; enzyme and CoA complex of yeast CT domain (Zhang
Alberts and Vagelos, 1972; Cronan and Waldrop, 2002; et al., 2003), as well as its complex with the herbicides
Wakil et al., 1983). The eukaryotic ACCs are large, multi- haloxyfop or diclofop (Zhang et al., 2004). The structures
domain enzymes and contain the biotin carboxylase reveal that the active site of the CT domain is located
(BC), biotin carboxyl carrier protein (BCCP), and carbox- at the interface of a dimer of the enzyme. The FOP
yltransferase (CT) domains (Figure 1A). The BC domain inhibitors are located in the dimer interface and inhibit
catalyzes the first step of the reaction, carboxylation of the enzyme by disrupting the binding or the conforma-
the biotin group that is covalently linked to BCCP, and tion of the acetyl-CoA or malonyl-CoA substrate, consis-
then the CT domain catalyzes the transfer of this acti- tent with our kinetic data demonstrating competitive
vated carboxyl group to the acetyl-CoA substrate. inhibition of haloxyfop versus malonyl-CoA. The binding
Two isoforms of ACCs are present in mammals. ACC1 of FOPs requires large conformational changes for sev-
is a cytosolic enzyme, and it controls the committed eral residues in the active site of the CT domain, espe-
step in the biosynthesis of long-chain fatty acids (Wakil cially Tyr1738 and Phe1956, as well as a change in the
et al., 1983). ACC2 is associated with the outer mem- organization of the dimer. The two residues that confer
resistance to the herbicides when mutated, equivalent
to Leu1705 and Val1967 of yeast ACC, are located in*Correspondence: tong@como.bio.columbia.edu
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Figure 1. CP-640186 and Its Complex with the CT Domain
(A) Domain organization of eukaryotic ACCs. BC, biotin carboxylase; BCCP, biotin carboxyl carrier protein; CT, carboxyltransferase. The
residue numbers are for yeast ACC.
(B) Chemical structure of R-CP-640186.
(C) Final omit 2Fo  Fc electron density at 2.8 A˚ resolution for CP-640186, contoured at 1.
(D) Schematic drawing of the structures of yeast CT domain dimer in complex with CP-640186 (in gold). The N domains of the two monomers
are colored in cyan and magenta, and the C domains are colored in yellow and green. The positions of haloxyfop (black) and CoA (gray) are
shown for reference. Panel (C) was produced with SETOR (Evans, 1993) and (D) with Ribbons (Carson, 1987).
the binding site and are the only residues that show the crystal structure of the yeast CT domain in complex
variations among the ACCs. with this compound at 2.8 A˚ resolution (Table 1). The
We present here the crystal structure of yeast CT complex with CP-640186 was obtained by soaking crys-
domain in complex with CP-640186 at 2.8 A˚ resolution. tals of the free enzyme with this compound, and the
The compound has tight associations with the active crystallographic analysis showed clearly defined elec-
site of the enzyme but has a distinct mechanism of
inhibiting the CT domain as compared to the FOPs. CP-
640186 may block the binding of the biotin substrate to Table 1. Summary of Crystallographic Information
the CT domain, and it requires essentially no conforma-
Resolution range for refinement (A˚) 30–2.8tional change in the CT domain for binding. Our studies
Number of observations 238,996
identify three regions in the active site of CT that can Rmergea (%) 5.7 (23.1)
be targeted for drug binding. We have developed a fluo- Number of reflections 92,729
rescence anisotropy binding assay that can measure Completeness (%) 86 (65)
R factorb (%) 19.7 (27.1)the affinity of CP-640186 and other inhibitors for the CT
Free R factorb (%) 23.4 (30.2)domain.
Rms deviation in bond lengths (A˚) 0.007
Rms deviation in bond angles () 1.3Results and Discussion
The numbers in parentheses are for the highest resolution shell.
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action of CP-640186 (Figure 1B), we have determined
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Figure 2. The Binding Mode of CP-640186
(A) Stereographic drawing showing the binding site for CP-640186. The N domain of one monomer is colored in cyan and the C domain of
the other monomer in green. The side chains of residues in the binding site are shown in yellow and magenta, respectively. The hydrogen
bonds from the inhibitor are shown as thin red lines. This panel was produced with Ribbons (Carson, 1987).
(B) Schematic drawing of the interactions between CP-640186 and the yeast CT domain.
(C) Molecular surface of the binding site for CP-640186 in the yeast CT domain. This panel was produced with Grasp (Nicholls et al., 1991).
tron density for the inhibitor (Figure 1C). The current electron density was observed based on the crystallo-
graphic analysis, but it could not be confidently interpre-atomic model has excellent agreement with the ob-
served diffraction data and the expected chemical pa- ted in terms of the amino acid sequence of the protein.
As a result, about 40 residues are absent from the cur-rameters (Table 1), and 86% of the residues are in the
most favored region of the Ramachandran plot (data rent atomic model at the C terminus. This additional
electron density is located in the dimer interface. Dele-not shown).
There are three molecules of the CT domain in the tion mutants missing the C-terminal segment are mono-
meric in solution and catalytically inactive (unpublishedcrystallographic asymmetric unit, and they have essen-
tially the same conformation. The rms distance between data).
equivalent C atoms of any pair of these monomers is
0.4 A˚. Two of the monomers form a noncrystallographic Binding Mode of CP-640186
CP-640186 is bound in the active site of the CT domain,dimer (Figure 1D), whereas the third monomer is situated
near the crystallographic 2-fold axis and forms a crystal- at the interface between the two monomers of the CT
dimer (Figure 1D). The compound is present in all threelographic dimer. The organization of these two dimers
is also similar, with rms distance of 0.4 A˚ for their equiva- independent active sites in the crystal, in essentially
the same conformation. The anthracene group of thelent C atoms.
The expression construct covers residues 1476–2233 inhibitor is held tightly between helix 6 in the N domain
and helix 6 in the C domain (with the prime indicatingof yeast ACC (Zhang et al., 2004), but several segments
of the protein are not included in the atomic model due to the second monomer) (Figure 2A). The structure sug-
gests that only a flat chemical moiety can fit in this partdisorder (Zhang et al., 2003, 2004). Residues 2048–2080
(helices 6B and 6C of the C domain), and about 10 of the binding site. The carbonyl oxygen atom next to
the anthracene group is hydrogen bonded to the mainresidues at the N terminus, are disordered in all three
monomers (Figure 1D). Near the C terminus, fragmented chain amide of Glu2026 near the beginning of helix 6,
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Figure 3. The Inhibitor Binding Sites Are Highly Conserved
Sequence alignment of residues in the CP-640186 (highlighted in gold), haloxyfop (in green), and CoA (in gray) binding pockets. The two
residues that confer herbicide resistance when mutated, Leu1705 and Val1967, are highlighted in red (Delye et al., 2003; Zagnitko et al., 2001).
A dash represents a residue that is identical to that in yeast ACC, whereas an equal sign represents a residue that is strictly conserved among
ACCs.
whereas that next to the morpholine ring is hydrogen full-length ACC enzyme actually has three biotin binding
sites, one each in the BC, BCCP, and CT domains. Thebonded to the main chain amide of Gly1958 (Figure 2B).
The geometry of the latter hydrogen bond is not optimal, biotin binding site in this paper refers to that in the
CT domain.) CP-640186 has no overlap with the boundas the angle between the carbonyl and the amide groups
is about 90 (Figure 2A). position of CoA in the active site (Figure 4B) (Zhang et
al., 2003), but the piperidyl rings are within 7 A˚ of theThe two piperidyl rings and the morpholino group are
all in the favored chair conformation (Figure 2A). They thiol group of CoA and approach the active site from
the opposite direction of CoA (Figure 4A). This is theare placed in a deep, mostly hydrophobic groove on the
surface of the active site (Figure 2C). One wall of this expected location of the biotin substrate of the CT en-
zyme. It is unlikely for the biotin substrate to approachgroove is formed by the side chains of Pro1920,
Val1923, Arg1954, and Glu2026 (Figure 2B), while the the active site from the direction of the CoA molecule,
as there will be steric hindrance between the two sub-other is formed by Thr1757, Ile1762, Met1765, and
Leu1766 from the 6 helix of the N domain (Figure 2A). strates. Therefore, the most likely direction for biotin to
approach the active site is from the opposite side ofWith the exception of Ile1762, Met1765, and Pro1920,
the other residues in this binding groove are strictly the CoA molecule, where the CP-640186 compound is
bound (Figure 4A).conserved among the ACCs (Figure 3, and see below).
Our structure suggests that the hydrophobic groove Our structural observation is supported by kinetic
studies with full-length ACC showing CP-640186 is non-that interacts with the piperidyl and the morpholino
groups of CP-640186 may also be the binding site for competitive versus the acetyl-CoA substrate (Harwood
et al., 2003), as well as our own kinetic studies with thethe biotin substrate in the CT domain (Figure 4A). (Each
Figure 4. Three Distinct Binding Regions in the Active Site of CT
(A) Molecular surface of the active site region of yeast CT. The CoA and CP-640186 molecules are shown in gray and gold, respectively. This
panel was produced with Grasp (Nicholls et al., 1991).
(B) Comparison of the binding modes of CP-640186 (in gold), haloxyfop (black), and CoA (gray). This panel was produced with Ribbons
(Carson, 1987).
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isolated CT domain (see below). The structural informa- not have any overlap in the CT active site (Figure 4B).
The conformation of Phe1956 in the herbicide complextion therefore predicts that CP-640186 should be a com-
petitive inhibitor with respect to the biotin substrate. is incompatible with CP-640186 binding. This residue is
located in strand 	7B of the C domain, whose mainOur attempts at demonstrating this pattern of inhibition
were not successful, due to the high Km (around 10 mM) chain is in direct contact with the CP-640186 inhibitor
(Figure 2A). Our binding studies confirm this predictionof the biotin substrate (Polakis et al., 1974).
The morpholine portion of CP-640186 is important for based on the structural information (see below).
high-affinity binding to the mammalian ACCs (Harwood
et al., 2003). The compound that has only a simple amino Inhibition of Yeast CT Domain by CP-640186
group at this position is a much weaker inhibitor, with To assess whether isolated CT domains can maintain
IC50 value of 1.8 
M (Harwood et al., 2003). Our structure similar affinity for the inhibitors as the full-length ACC
shows that the morpholine ring is situated in the hy- enzymes, we carried out kinetic and fluorescence bind-
drophobic groove (Figure 2C), consistent with its impor- ing studies to characterize the inhibition of the yeast CT
tance for binding affinity. At the same time, there ap- domain by CP-640186. Kinetic studies show that the
pears to be additional space near this group in the compound has an IC50 value of about 8 
M (Figure 5A).binding site (Figure 2C). This is supported by the obser- It is a noncompetitive inhibitor with respect to the sub-
vation that compounds that replace the morpholine ring strate malonyl-CoA (Figure 5B), with inhibitory constants
with bulkier groups, such as diisopropylamine, are more of 4.9 and 6.0
M for Kii and Kis, respectively. This patternpotent than CP-640186 (Harwood et al., 2003). of inhibition is consistent with results from kinetic stud-
The structure of the complex also explains the molec- ies on the full-length ACCs (Harwood et al., 2003) as
ular basis for the stereoselectivity of the binding (Har- well as our structural observation.
wood et al., 2003). The R stereoisomer of CP-640186 The inhibitory potency against the isolated CT domain
allows interactions between the morpholino group and from yeast ACC is essentially the same as that against
the CT domain, while this group in the S stereoisomer full-length ACCs from other fungal sources (IC50 valueswould be projected out of the binding site, possibly for the closely related diethylamide derivative, CP-
also having steric clashes with the enzyme (Figure 2C). 610431, of 6 
M against Candida ACC and 1 
M against
Indeed, the R and S stereoisomers of the closely related Aspergillus ACC) (Harwood et al., 2003). This demon-
diethylamide derivative (CP-610431 and CP-610432, re- strates that the other domains of fungal ACCs may only
spectively [Harwood et al., 2003]) inhibit rat liver ACC1 have a minor role in the binding of CP-640186, and
with IC50 values of 36 and 5000 nM, respectively (H.J. suggests that the isolated CT domains, in addition to the
Harwood, personal communication). full-length ACCs, can serve as a direct drug discovery
There are only minor conformational changes in the target.
CT domain upon inhibitor binding. The overall structure The presence of the anthracene fluorophore in CP-
of the CT domain, as well as the organization of the 640186 allowed us to develop a fluorescence anisotropy
dimer, in the CP-640186 complex is essentially the same assay that directly measures the binding affinity be-
as that of the free enzyme that we reported earlier (Zhang tween the inhibitor and the CT domain. The observed
et al., 2003, 2004). titration curve (fluorescence anisotropy versus CT do-
main concentration) can be readily fit to a 1:1 binding
model (Figure 5C), giving a Kd value of 7.2
M, essentiallyDistinct Mechanisms for Inhibiting the CT Domain
the same as the kinetic observations. This confirms thatBoth CP-640186 and the herbicides are potent inhibitors
there is only one binding site for CP-640186 in each CTof their target ACCs (Devine and Shukla, 2000; Gron-
domain.wald, 1991; Harwood et al., 2003), and our structural
As our structural data suggest that CP-640186 andstudies demonstrate that both compounds function at
the FOPs herbicides should be competitive in their bind-the active site of the CT domain (Figure 1D) (Zhang
ing to the CT domain, we next performed a competitionet al., 2004). However, CP-640186 and the FOPs have
binding assay. The decrease in fluorescence anisotropydistinct mechanisms for inhibiting the CT activity, as
of CP-640186 in the presence of haloxyfop confirmedthey have no overlap in their bound positions (Figure
the competitive nature of the binding (Figure 5D). The4B). While CP-640186 may utilize the putative biotin
affinity of haloxyfop for the CT domain can be deducedbinding site of the CT domain, the FOPs are bound in
from the observed data, and the resulting Kd value ofan allosteric site that is unlikely to be occupied by either
200 
M is in good agreement with the Ki value of 250 
Msubstrate of the enzyme during catalysis (Zhang et al.,
that we determined from kinetic studies earlier (Zhang et2004).
al., 2003).Moreover, herbicide binding requires changes in the
conformation of several residues in the dimer interface,
as well as in the organization of the dimer (Zhang et al., Inhibition of Human CT Domain by CP-640186
and CP-6401882004). This is in sharp contrast to our observations on
the complex with CP-640186, where the compound is We have produced small amounts of the CT domain
of human ACC1 by expression in bacteria, and kineticassociated with a preformed binding site.
As a consequence of these conformational changes, studies confirm that this CT domain is catalytically active
(data not shown). The fluorescence anisotropy bindingCP-640186 and the FOPs should be competitive with
each other for binding to the CT domain, although this assay developed using the yeast CT domain allowed us
to characterize the inhibition of the human CT by CP-is an indirect competition, as the two compounds do
Structure
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Figure 5. The Inhibition of Yeast CT Domain
The data from one representative experiment of several duplicates are shown.
(A) Titration curve for the determination of the IC50 value of CP-640186 against the yeast CT domain.
(B) Double reciprocal plot showing the noncompetitive inhibition of the yeast CT domain by CP-640186. Red, 0 
M; green, 3 
M; and blue,
10 
M CP-640186.
(C) Plot of the fluorescence anisotropy of CP-640186 as a function of yeast CT domain concentration. The observed binding curve can be fit
to a 1:1 binding model.
(D) The fluorescence anisotropy of CP-640186 as a function of the concentration of the haloxyfop competitor.
640186 and its more potent analog, CP-640188, which Conservation of the Binding Site
The CT domains of yeast and human ACCs share 50%contains the diisopropylamide moiety in place of the
morpholine ring (Harwood et al., 2003). The Kd values amino acid sequence identity overall. In the active site
region, the degree of sequence conservation is evenfor the isolated CT domains as determined from the
binding assays are 1.2 and 0.5 
M for CP-641086 and higher (Figure 3). It may be expected that the binding
mode of CP-640186 to the mammalian CT domainsCP-640188, respectively (Figure 6).
The observed Kd values for the CT domain are 20–50 should be the same as that to the yeast CT domain
reported here. Most of the residues that directly contactfold higher than the IC50 values of these compounds
against full-length rat ACCs (55 and 10 nM, respectively) the CP-640186 inhibitor are strictly conserved among
the ACCs (Figure 3). In fact, all the residues in the binding(Harwood et al., 2003). One possible explanation for this
difference is that other domains of mammalian ACCs, site for CP-640186 are identical between human ACC1
and ACC2 (Figure 3), consistent with the potent activityespecially BCCP, might play a role in the binding of CP-
640186. Part of the morpholine ring is exposed to the of this compound against both isoforms of mammalian
ACCs (Harwood et al., 2003).solvent in the complex (Figure 2C). It may be possible
that the BCCP domain, which carries the biotin substrate Ile1762, Met1765, and Pro1920 near the piperidyl and
morpholino groups, and Gln2028, Met2030, and Gly2032in the full-length enzyme, helps shield this ring from the
solvent and thereby enhances the binding affinity of CP- near the anthracene group, are the only residues that
show differences between the yeast and human ACCs640186 to the mammalian ACCs. Our data with the yeast
CT domain suggest the other domains of fungal ACCs in this binding site (Figure 3). To assess the impact of
these variations on the affinity for CP-640186, we cre-may have only a minor role in binding CP-640186, but
there are biochemical differences between the mamma- ated three single-site mutants, I1762L, M1765V, and
G2032E, of the yeast CT domain, which introduced thelian and fungal ACCs. For example, the mammalian en-
zyme is activated by citrate (Wakil et al., 1983), and equivalent residue from human ACCs. These three resi-
dues were chosen because it appears they makethe IC50 values for CP-640186 were measured in the
presence of this activator (Harwood et al., 2003). It would stronger contacts with CP-640186 (Figure 2A). Our ki-
netic and binding data show that the I1762L and G2032Ebe interesting to determine whether citrate has an im-
pact on the IC50 value of the compound. mutations have only minor effects on the catalytic activ-
Structure of CT Domain in Complex with CP-640186
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Figure 6. The Inhibition of the CT Domain of Human ACC1
Plot of the fluorescence anisotropy of CP-640186 (red) or CP-640188 (green) as a function of CT domain concentration.
ity of the CT domain and the affinity for CP-640186 (data While the CoA and the putative biotin regions corre-
spond to substrate binding sites, the herbicide bindingnot shown). The M1765V mutant did not produce enough
soluble enzyme for kinetic or binding studies. It remains region is an allosteric binding surface and requires large
conformational changes for two strictly conserved resi-to be seen whether a mutant carrying all the changes at
the same time can have higher affinity for the compound. dues near the active site of the enzyme, Tyr1738 and
Phe1956 (Zhang et al., 2004). Conformational changesIt is possible that the specificity of mammalian ACCs
for CP-640186 is determined by residues outside the in the active site have been observed in other drug
discovery targets, for example in the binding of Gleevecimmediate binding site. We have observed a similar situ-
ation for the herbicides, where mutation of residues that to the Abelson tyrosine kinase (Schindler et al., 2000)
and the binding of potent inhibitors to p38 MAP kinasedirectly contact haloxyfop is not sufficient to make the
yeast CT domain sensitive to the compound (Zhang et (Pargellis et al., 2002).
Although both CP-640186 and the herbicides wereal., 2004). In addition, as discussed above, other do-
mains of mammalian ACCs, for example BCCP, may originally identified based on their inhibition of full-
length ACCs, the large size of these enzymes (Figurealso play a role in the binding of CP-640186, providing
another mechanism for the potent inhibition of the mam- 1A) essentially precludes any detailed structural studies
of the interactions between the inhibitors and the full-malian ACCs by these compounds.
length enzymes. Therefore, the characterization of inhib-
itor binding to the CT domain may represent the onlyThree Distinct Regions for Drug Discovery
means of elucidating the molecular basis of their ac-in the Active Site of CT
tions. Our structural and kinetic studies demonstrateOur structural studies of the substrate and inhibitor com-
that these compounds have intimate associations withplexes of the CT domain reveal that the active site of
the CT domain and potently inhibit its activity. This sug-this enzyme has three distinct regions for binding small
gests that the CT domain itself may also be a valid targetmolecules—the CoA binding region, the putative biotin
for the development of inhibitors against the ACCs. Thebinding region, and the herbicide binding region (Figure
three binding regions in this domain identified from our4B). There is little overlap among the three regions, and
studies should allow the design and development ofthe relevance of these regions for drug discovery is
new, potent inhibitors against these important therapeu-illustrated by the fact that inhibitors with nanomolar po-
tic targets.tency have already been developed utilizing the biotin
and the herbicide binding regions. It is likely that potent
Experimental Proceduresinhibitors can also be developed against the CoA bind-
ing region. It is also conceivable that compounds that Protein Production and Crystallization
bridge the different regions could also be potent inhibi- The cloning, expression, purification, and crystallization of the CT
domain (residues 1476–2233) of yeast ACC followed protocols astors of the CT activity.
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